x

Posted 12 November, 2021

Bellerophon Therapeutics, Inc. appointed Peter Fernandes as new CEO

OTC:BLPH appointed new Chief Executive Officer Peter Fernandes in a 8-K filed on 12 November, 2021.


  On November 11, 2021, the Board of Directors of Bellerophon Therapeutics, Inc. (the "Company"), appointed Peter Fernandes to serve as Interim Principal Executive Officer of the Company, effective November 11, 2021, while the Board conducts a search for its next Chief Executive Officer.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Bellerophon Therapeutics, Inc.
Health Care/Life Sciences • Pharmaceuticals
Bellerophon Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Its product pipeline includes PH-ILD, PH-COPD, INOpulse and PH-Sarc. The company was founded in 2009 and is headquartered in Warren, NJ.
Market Cap
$630K
View Company Details
Bellerophon Therapeutics, Inc. by TradingView
Relevant filing section
Item 5.02. Departure of Directors or Certain Officers; Election of Directs; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Interim Principal Executive Officer


On November 11, 2021, the Board of Directors of Bellerophon Therapeutics, Inc. (the "Company"), appointed Peter Fernandes to serve as Interim Principal Executive Officer of the Company, effective November 11, 2021, while the Board conducts a search for its next Chief Executive Officer. Mr. Fernandes currently serves as the Company's Chief Regulatory & Safety Officer and will additionally continue in that role. No family relationships exist between Mr. Fernandes and any of our directors or executive officers. There are no arrangements or understandings between Mr. Fernandes and any other person pursuant to which he was selected as the Interim Principal Executive Officer. Mr. Fernandes will not receive any additional compensation as Interim Principal Executive Officer. Mr. Fernandes does not have a direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.


Peter Fernandes has been our Chief Regulatory and Safety Officer since May 2015. Prior to joining us, Mr. Fernandes was Vice President of Global Regulatory Affairs at Ikaria Inc., from October 2012 to May 2015, and in this capacity also led our regulatory group since its inception in February of 2014. Previously, he led Regulatory Affairs and Quality Assurance for OptiNose, Inc. from October 2010 to September 2012, was Vice President US Drug Regulatory Affairs Respiratory and US DRA Respiratory Franchise Head for Novartis Pharmaceuticals from November 2007 to October 2010. He has also served as the Head of US Development Site and Vice President of Regulatory Affairs and Quality Assurance at Altana Pharma, a subsidiary of Nycomed Inc., and led the US Respiratory and GI Drug Regulatory Affairs group at Boehringer Ingelheim. Mr. Fernandes has an M. Pharm. from the Grant Medical College and a B. Pharm. from the K.M.K. College of Pharmacy, both at the University of Bombay in India.






2